Q1 2026 Clinical Recap: 7 FDA-Approved Treatments for Neurologists to Know

The first quarter of 2026 represented a notable period of progress in neurological care, highlighted by several FDA drug approvals targeting complex and rare conditions. These included first-of-their-kind therapies for ultra-rare disorders such as neurologic Hunter syndrome and cerebral folate transport deficiency, as well as new treatment formulations for spinal muscular atrophy (SMA). Collectively, these regulatory decisions reflect continued developments in the management of neurologic diseases.